EUVIMEDEUVIMED entdecken
Übersichtsarbeit

FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid

Kang Wang, Yuecan Zhang, Guangji Wang, Haiping Hao iD, Hong Wang iD

Medicinal Research Reviews · 2024-03 · 44 (2) · 568-586

DOI: 10.1002/med.21991 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 30.10.2023. Verfasst von Kang Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 129-mal zitiert (Crossref) und nennt 103 Literaturangaben. Gefördert von: Major State Basic Research Development Program of China, National Natural Science Foundation of China, Project of State Key Laboratory of Natural Medicines, China Pharmaceutical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nonalcoholic fatty liver disease, also called metabolic dysfunction‐associated steatotic liver disease, is the most common liver disease worldwide and has no approved pharmacotherapy. Due to its beneficial effects on metabolic regulation, inflammation suppression, cell death prevention, and fibrogenesis inhibition, farnesoid X receptor (FXR) is widely accepted as a promising therapeutic target for nonalcoholic steatosis (NASH) or called metabolic dysfunction‐associated steatohepatitis (MASH). Many FXR agonists have been developed for NASH/MASH therapy. Obeticholic acid (OCA) is the pioneering frontrunner FXR agonist and the first demonstrating success in clinical trials. Unfortunately, OCA did not receive regulatory approval as a NASH pharmacotherapy because its moderate benefits did not outweigh its safety risks, which may cast a shadow over FXR‐based drug development for NASH/MASH. This review summarizes the milestones in the development of OCA for NASH/MASH and discuss its limitations, including moderate hepatoprotection and the undesirable side effects of dyslipidemia, pruritus, cholelithiasis, and liver toxicity risk, in depth. More importantly, we provide perspectives on FXR‐based therapy for NASH/MASH, hoping to support a successful bench‐to‐clinic transition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseHumansChenodeoxycholic Acid

Stichwörter der Autor:innen

agonistfarnesoid X receptor (FXR)metabolic dysfunction-associated steatotic liver disease (MASLD)nonalcoholic fatty liver disease (NAFLD)obeticholic acid (OCA)

Substanzen

obeticholic acidChenodeoxycholic Acid

Autor:innen und Institutionen

  • State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.

ORCID-Profile: Haiping Hao, Hong Wang

Förderung

  • Major State Basic Research Development Program of China
  • National Natural Science Foundation of China
  • Project of State Key Laboratory of Natural Medicines, China Pharmaceutical University
  • Leading technology foundation research project of Jiangsu province
  • Overseas Expertise Introduction Project for Discipline Innovation

Zitieren

APA

Wang, K., Zhang, Y., Wang, G., Hao, H., & Wang, H. (2024). FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid. Medicinal Research Reviews, 44(2), 568-586. https://doi.org/10.1002/med.21991

Vancouver

Wang K, Zhang Y, Wang G, Hao H, Wang H. FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid. Medicinal Research Reviews. 2024;44(2):568-586. doi:10.1002/med.21991

BibTeX
@article{Wang2024,
  author = {Wang, Kang and Zhang, Yuecan and Wang, Guangji and Hao, Haiping and Wang, Hong},
  title = {FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid},
  journal = {Medicinal Research Reviews},
  year = {2024},
  volume = {44},
  number = {2},
  pages = {568--586},
  doi = {10.1002/med.21991}
}
Kostenlos starten →